Perphenazine

Generic Name: Perphenazine

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆ClN_₃OS

CAS Number: 58-39-9

Unique Ingredient Identifier: FTA7XXY4EZ

Overview

An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

Indication

For use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.

Associated Conditions

Anxiety
Depression
Schizophrenia
Moderate Agitation
Moderate Anxiety
Moderate Depressed mood
Severe Anxiety
Severe Depressed mood
Severe Nausea and vomiting
Severe agitation

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE	2023/03/09	NCT05762146	Phase 2	Recruiting	Maastricht University
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers	2021/03/01	NCT04776499	Phase 1	Completed	Maastricht University
Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data	2020/10/28	NCT04606264	Phase 3	Recruiting	Jennifer Holder-Murray
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies	2016/09/08	NCT02893371	N/A	Terminated	University of New Mexico
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)	2015/11/09	NCT02600741	N/A	Completed	Janssen Scientific Affairs, LLC
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform	2015/05/01	NCT02431702	Phase 3	Completed	Janssen Scientific Affairs, LLC
Pharmacovigilance in Gerontopsychiatric Patients	2015/03/02	NCT02374567	Phase 3	Terminated	Hannover Medical School
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients	2014/12/04	NCT02307396	Phase 4	Completed	Technical University of Munich
Lurasidone Effects on Tissue Glutamate in Schizophrenia	2014/07/24	NCT02199743	Phase 4	Completed	University of Texas Southwestern Medical Center
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital	2010/09/01	NCT01193166	Phase 4	Withdrawn	Ortho-McNeil Janssen Scientific Affairs, LLC

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Perphenazine	State of Florida DOH Central Pharmacy	53808-0665	ORAL	4 mg in 1 1	8/18/2010
Perphenazine and Amitriptyline Hydrochloride	Mylan Pharmaceuticals Inc.	0378-0042	ORAL	4 mg in 1 1	9/26/2019
Perphenazine	Actavis Pharma, Inc.	0591-4103	ORAL	8 mg in 1 1	5/31/2017
PERPHENAZINE	Proficient Rx LP	71205-843	ORAL	8 mg in 1 1	2/1/2023
Perphenazine	Bryant Ranch Prepack	72162-1163	ORAL	4 mg in 1 1	9/16/2022
Perphenazine	State of Florida DOH Central Pharmacy	53808-0762	ORAL	16 mg in 1 1	8/18/2010
perphenazine	Zydus Pharmaceuticals (USA) Inc.	68382-594	ORAL	16 mg in 1 1	9/30/2023
Perphenazine	Major Pharmaceuticals	0904-6601	ORAL	8 mg in 1 1	12/18/2018
Perphenazine and Amitriptyline Hydrochloride	Mylan Pharmaceuticals Inc.	0378-0442	ORAL	2 mg in 1 1	9/26/2019
Perphenazine	Bryant Ranch Prepack	63629-2251	ORAL	4 mg in 1 1	4/6/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
APO-PERPHENAZINE TABLET 8 mg	APOTEX INC	SIN00437P	TABLET, FILM COATED	8 mg	4/27/1988
APO-PERPHENAZINE TABLET 4 mg	APOTEX INC	SIN00444P	TABLET, FILM COATED	4 mg	4/27/1988

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
PERPHENAZINE	aa pharma inc	00335118	Tablet - Oral	8 MG	12/31/1976
PHENAZINE 4 TAB	icn canada ltd.	00296317	Tablet - Oral	4 MG / TAB	12/31/1973
PERPHENAZINE TAB 4MG	PRO DOC LIMITEE	00563749	Tablet - Oral	4 MG	12/31/1982
PERPHENAZINE 2 TAB 2MG	PRO DOC LIMITEE	00563757	Tablet - Oral	2 MG	12/31/1982
PMS PERPHENAZINE TAB 8MG	Pharmascience Inc	00726281	Tablet - Oral	8 MG	12/31/1987
PMS PERPHENAZINE TAB 4MG	Pharmascience Inc	00726192	Tablet - Oral	4 MG	12/31/1987
PERPHENAZINE	aa pharma inc	00335134	Tablet - Oral	2 MG	12/31/1976
PERPHENAZINE 16 TAB	PRO DOC LIMITEE	00563722	Tablet - Oral	16 MG	12/31/1982
PERPHENAZINE	aa pharma inc	00335096	Tablet - Oral	16 MG	12/31/1976
PERPHENAZINE TAB 4MG	d.c. labs limited	00456047	Tablet - Oral	4 MG	12/31/1979

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

NetraMark to Present AI-Powered Clinical Trial Analysis Tools for Psychiatric Disorders at ISCTM Meeting

5 months ago

NetraMark will showcase novel AI-based tools that demonstrate 28% improved accuracy in predicting treatment responses for major depressive disorder clinical trials at the ISCTM Annual Meeting.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.